openPR Logo
Press release

Retinal Disorders – Therapy Market Snapshot

11-08-2017 09:05 AM CET | Health & Medicine

Press release from: ReportsWorldwide

Boston, MA

ReportsWorldwide has announced the addition of a new report title Retinal Disorders – Therapy Market Snapshot to its growing collection of premium market research reports.

A range of disorders, some of which share similar underlying pathologies, can affect the retina and lead to progressively worsening vision and eventual blindness. The retina is the layer of light-sensitive tissue at the back of the eye that converts light into impulses to the brain via the optic nerve. A common feature of certain retinal disorders is abnormal growth of blood vessels in the macula, which can be effectively treated by drugs targeting vascular endothelial growth factor. These discrete indications are wet age-related macular degeneration, diabetic retinopathy with and without diabetic macular edema, and macular edema from retinal vein occlusion.

The report of 142 pages, 40 tables and 35 figures covers the below topics in detail:

• Treatment
• Marketed Drugs –Profiles of Avastin, Eylea, Lucentis and Ozurdex
• Drug Pipeline – Late stage product profiles of Zuprata, abicipar pegol, brolucizumab and squalamine

For a Detailed description and table of contents of this Datamonitor Healthcare report please click here: https://www.reportsworldwide.com/report/retinal-disorders

Below is a Snapshot of Retina Disorders therapy market :

• New therapies will sustain market growth beyond expiries for first-generation anti-VEGF injections.
• Anti-VEGFs lead treatment dynamics, although choice of specific therapy is widely variable between countries.
• Common retinal disorders will contribute to over four million cases in 2016; this is expected to rise in the future.
• Eylea has become the clinical gold standard and market-leading anti-VEGF therapy.
• Brolucizumab’s Phase III data position it as a direct competitor to the $5bn VEGF inhibitor Eylea.

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=42264

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-1947
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retinal Disorders – Therapy Market Snapshot here

News-ID: 806682 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for VEGF

Anti-VEGF Therapeutics Market In-Deep Research and Forecast Report
The revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities. Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anti-vascular-endothelial-growth-factor-therapeutics-market/report-sample Eylea held the largest share in the
(Post-pandemic Era) - VEGF Antibody Market Future Developments and Industry Size …
According to Research study, over the next 5 years the (Post-pandemic Era) - VEGF Antibody market will register a xx% CAGR in terms of revenue, the global market size will reach xx Million USD by 2026, from xx Million USD in 2020. In particular, it should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply
Global VEGF/VEGFR Inhibitor Drugs Industry Research Analysis by 2020- 2025
This report also researches and evaluates the impact of Covid-19 outbreak on the VEGF/VEGFR Inhibitor Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on VEGF/VEGFR Inhibitor Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global and Japan VEGF/VEGFR Inhibitor Drugs Market 2020 by Company, Type and Application, Forecast to
Vascular Endothelial Growth Factor (VEGF) Antibodies Market By 2026 Genentech, N …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Opportunity Analysis …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Report Explored in L …
Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Overview Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals. Currently, VEGF antibodies used for treating